HRP20100363T1 - Nove kombinacije antagonista receptora 5-ht3 s racekatodrilom ili deksekatodrilom - Google Patents

Nove kombinacije antagonista receptora 5-ht3 s racekatodrilom ili deksekatodrilom Download PDF

Info

Publication number
HRP20100363T1
HRP20100363T1 HR20100363T HRP20100363T HRP20100363T1 HR P20100363 T1 HRP20100363 T1 HR P20100363T1 HR 20100363 T HR20100363 T HR 20100363T HR P20100363 T HRP20100363 T HR P20100363T HR P20100363 T1 HRP20100363 T1 HR P20100363T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical preparation
combination
diarrhea
treatment
combination according
Prior art date
Application number
HR20100363T
Other languages
English (en)
Croatian (hr)
Inventor
Schwartz Jean-Charles
Lecomte Jeanne-Marie
Original Assignee
Bioprojet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34684783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100363(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioprojet filed Critical Bioprojet
Publication of HRP20100363T1 publication Critical patent/HRP20100363T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HR20100363T 2004-02-12 2005-02-14 Nove kombinacije antagonista receptora 5-ht3 s racekatodrilom ili deksekatodrilom HRP20100363T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04290384A EP1563848A1 (en) 2004-02-12 2004-02-12 New combinations of an anti-emetic agent and an enkephalinase inhibitor
PCT/IB2005/000351 WO2005079850A1 (en) 2004-02-12 2005-02-14 New combinations of an anti emetic agent and an enkephalinase inhibitor

Publications (1)

Publication Number Publication Date
HRP20100363T1 true HRP20100363T1 (hr) 2010-07-31

Family

ID=34684783

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100363T HRP20100363T1 (hr) 2004-02-12 2005-02-14 Nove kombinacije antagonista receptora 5-ht3 s racekatodrilom ili deksekatodrilom

Country Status (28)

Country Link
US (1) US8222294B2 (enExample)
EP (2) EP1563848A1 (enExample)
JP (1) JP4987487B2 (enExample)
KR (1) KR101152308B1 (enExample)
CN (1) CN1917903B (enExample)
AT (1) ATE468138T1 (enExample)
AU (1) AU2005215262B2 (enExample)
BR (1) BRPI0506631B8 (enExample)
CA (1) CA2553827C (enExample)
CY (1) CY1110202T1 (enExample)
DE (1) DE602005021317D1 (enExample)
DK (1) DK1718337T3 (enExample)
EA (1) EA010625B1 (enExample)
EC (1) ECSP066758A (enExample)
ES (1) ES2344909T3 (enExample)
HR (1) HRP20100363T1 (enExample)
MA (1) MA28354A1 (enExample)
ME (1) ME01175B (enExample)
NO (1) NO337320B1 (enExample)
NZ (1) NZ548635A (enExample)
PL (1) PL1718337T3 (enExample)
PT (1) PT1718337E (enExample)
RS (1) RS51329B (enExample)
SI (1) SI1718337T1 (enExample)
TN (1) TNSN06246A1 (enExample)
UA (1) UA88156C2 (enExample)
WO (1) WO2005079850A1 (enExample)
ZA (1) ZA200605872B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2900823B1 (fr) * 2006-05-15 2009-02-13 Bioprojet Soc Civ Ile Nouvelle forme d'administration du racecadotril.
EP2462922A1 (en) * 2010-12-10 2012-06-13 Bioprojet New form of administration of enkephalinase inhibitor
EP2866789B1 (en) 2012-06-28 2018-08-01 Johnson & Johnson Consumer Inc. Racecadotril lipid compositions
US9114171B2 (en) * 2012-06-28 2015-08-25 Mcneil-Ppc, Inc. Racecadotril liquid compositions
US9801819B2 (en) * 2012-06-28 2017-10-31 Johnson & Johnson Consumer Inc. Racecadotril compositions
PT2866802T (pt) * 2012-06-28 2016-09-05 Johnson & Johnson Consumer Inc Composições líquidas racecadotril
MA40859A (fr) 2014-10-29 2017-09-05 Johnson & Johnson Consumer Inc Particules de cadotril

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins

Also Published As

Publication number Publication date
ATE468138T1 (de) 2010-06-15
CY1110202T1 (el) 2015-01-14
DK1718337T3 (da) 2010-07-26
JP4987487B2 (ja) 2012-07-25
CA2553827C (en) 2012-08-07
SI1718337T1 (sl) 2010-08-31
AU2005215262B2 (en) 2011-03-03
MA28354A1 (fr) 2006-12-01
US8222294B2 (en) 2012-07-17
ECSP066758A (es) 2006-11-24
KR20060132691A (ko) 2006-12-21
BRPI0506631B8 (pt) 2021-05-25
KR101152308B1 (ko) 2012-06-11
CA2553827A1 (en) 2005-09-01
NO20063973L (no) 2006-09-05
EP1718337B1 (en) 2010-05-19
US20070275993A1 (en) 2007-11-29
AU2005215262A1 (en) 2005-09-01
ZA200605872B (en) 2008-01-08
BRPI0506631A (pt) 2007-05-08
EP1718337A1 (en) 2006-11-08
JP2007522202A (ja) 2007-08-09
NO337320B1 (no) 2016-03-07
EA010625B1 (ru) 2008-10-30
PT1718337E (pt) 2010-06-16
DE602005021317D1 (de) 2010-07-01
NZ548635A (en) 2009-10-30
CN1917903A (zh) 2007-02-21
CN1917903B (zh) 2010-07-21
WO2005079850A1 (en) 2005-09-01
ES2344909T3 (es) 2010-09-09
BRPI0506631B1 (pt) 2018-12-04
ME01175B (me) 2013-03-20
EP1563848A1 (en) 2005-08-17
EA200601466A1 (ru) 2006-12-29
RS51329B (sr) 2011-02-28
UA88156C2 (ru) 2009-09-25
TNSN06246A1 (fr) 2007-12-03
PL1718337T3 (pl) 2010-09-30

Similar Documents

Publication Publication Date Title
SI2529622T1 (en) Inhibitors of bruton's tyrosine kinase
MX2010008234A (es) Nueva dosificacion y formulacion.
WO2007103557A3 (en) Coating capsules with active pharmaceutical ingredients
NZ605888A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
WO2005046640A3 (en) Multi-site drug delivery platform
MY177027A (en) Novel dosage and formulation
Gandara et al. Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy: dose, schedule, and route of administration
TR200101927T2 (tr) Etkin maddelerin geliştirilmiş bir şekilde verilmesini sağlayan bileşimler.
AR059324A2 (es) Una forma solida de dosificacion oral
BR0206627A (pt) Formulação farmacêutica
AR026745A1 (es) Composiciones de eplerenona nanoparticulada
HRP20240082T1 (hr) Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti
RU2010147287A (ru) Комбинированная композиция
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
SI2729130T1 (en) Combined formulations of darunavir
UY29905A1 (es) Formulación farmacéutica de absorción oral y su método de administración
RU2009116834A (ru) Способ введения лекарственных средств для снижения веса
AP2003002763A0 (en) Controlled release formulations for oral administration
CU22838A3 (es) Composiciones para controlar colonización bacteriana
HRP20161340T1 (hr) Formulacije darunavira
AR012480A1 (es) Una unidad de dosis farmaceutica que comprende tibolona, un metodo para elaborarla y el uso de un producto de almidon como vehiculo en unidades dedosis farmaceuticas que comprenden tibolona
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
TR200101929T2 (tr) Geliştirilmiş kararlılığa sahip bileşimler.
AR035429A1 (es) Kit y composicion farmaceutica que contienen compuestos quimioterapeuticos
JP2007522202A5 (enExample)